# Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies

> **NCT03405337** · — · COMPLETED · sponsor: **Bayer** · enrollment: 160 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** FVIII products
- **DRUG:** Conventional FVIII replacement therapies

## Key facts

- **NCT ID:** NCT03405337
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-14
- **Primary completion:** 2018-06-13
- **Final completion:** 2018-06-13
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2018-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03405337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03405337, "Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03405337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*